Is fidaxomicin worth the cost? An economic analysis

Sarah Bartsch, Craig A. Umscheid, Neil Fishman, Bruce Lee

Research output: Contribution to journalArticle

Abstract

Background. In May 2011, the Food and Drug Administration approved fidaxomicin for the treatment of Clostridium difficile infection (CDI). It has been found to be noninferior to vancomycin; however, its cost-effectiveness for the treatment of CDI remains undetermined. Methods. We developed a decision analytic simulation model to determine the economic value of fidaxomicin for CDI treatment from the third-party payer perspective. We looked at CDI treatment in these 3 cases: (1) no fidaxomicin, (2) only fidaxomicin, and (3) fidaxomicin based on strain typing results. Results. The incremental cost-effectiveness ratio for fidaxomicin based on screening given current conditions was >$43.7 million per quality-adjusted life-year and using only fidaxomicin was dominated (ie, more costly and less effective) by the other 2 treatment strategies explored. The fidaxomicin strategy tended to remain dominated, even at lower costs. With approximately 50% of CDI due to the NAP1/BI/027 strain, a course of fidaxomicin would need to cost ≤$150 to be cost-effective in the treatment of all CDI cases and between $160 and $400 to be cost-effective for those with a non-NAP1/BI/027 strain (ie, treatment based on strain typing). Conclusions. Given the current cost and NAP1/BI/027 accounting for approximately 50% of isolates, using fidaxomicin as a first-line treatment for CDI is not cost-effective. However, typing and treatment with fidaxomicin based on strain may be more promising depending on the costs of fidaxomicin.

Original languageEnglish (US)
Pages (from-to)555-561
Number of pages7
JournalClinical Infectious Diseases
Volume57
Issue number4
DOIs
StatePublished - Aug 15 2013
Externally publishedYes

Fingerprint

Clostridium Infections
Economics
Clostridium difficile
Costs and Cost Analysis
Cost-Benefit Analysis
lipiarmycin
Health Insurance Reimbursement
Quality-Adjusted Life Years
United States Food and Drug Administration
Vancomycin

Keywords

  • Clostridium difficile
  • Cost
  • Economics
  • fidaxomicin
  • Treatment

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

Is fidaxomicin worth the cost? An economic analysis. / Bartsch, Sarah; Umscheid, Craig A.; Fishman, Neil; Lee, Bruce.

In: Clinical Infectious Diseases, Vol. 57, No. 4, 15.08.2013, p. 555-561.

Research output: Contribution to journalArticle

Bartsch, Sarah ; Umscheid, Craig A. ; Fishman, Neil ; Lee, Bruce. / Is fidaxomicin worth the cost? An economic analysis. In: Clinical Infectious Diseases. 2013 ; Vol. 57, No. 4. pp. 555-561.
@article{655937fdea7940c4abc34a01edca90f2,
title = "Is fidaxomicin worth the cost? An economic analysis",
abstract = "Background. In May 2011, the Food and Drug Administration approved fidaxomicin for the treatment of Clostridium difficile infection (CDI). It has been found to be noninferior to vancomycin; however, its cost-effectiveness for the treatment of CDI remains undetermined. Methods. We developed a decision analytic simulation model to determine the economic value of fidaxomicin for CDI treatment from the third-party payer perspective. We looked at CDI treatment in these 3 cases: (1) no fidaxomicin, (2) only fidaxomicin, and (3) fidaxomicin based on strain typing results. Results. The incremental cost-effectiveness ratio for fidaxomicin based on screening given current conditions was >$43.7 million per quality-adjusted life-year and using only fidaxomicin was dominated (ie, more costly and less effective) by the other 2 treatment strategies explored. The fidaxomicin strategy tended to remain dominated, even at lower costs. With approximately 50{\%} of CDI due to the NAP1/BI/027 strain, a course of fidaxomicin would need to cost ≤$150 to be cost-effective in the treatment of all CDI cases and between $160 and $400 to be cost-effective for those with a non-NAP1/BI/027 strain (ie, treatment based on strain typing). Conclusions. Given the current cost and NAP1/BI/027 accounting for approximately 50{\%} of isolates, using fidaxomicin as a first-line treatment for CDI is not cost-effective. However, typing and treatment with fidaxomicin based on strain may be more promising depending on the costs of fidaxomicin.",
keywords = "Clostridium difficile, Cost, Economics, fidaxomicin, Treatment",
author = "Sarah Bartsch and Umscheid, {Craig A.} and Neil Fishman and Bruce Lee",
year = "2013",
month = "8",
day = "15",
doi = "10.1093/cid/cit346",
language = "English (US)",
volume = "57",
pages = "555--561",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Is fidaxomicin worth the cost? An economic analysis

AU - Bartsch, Sarah

AU - Umscheid, Craig A.

AU - Fishman, Neil

AU - Lee, Bruce

PY - 2013/8/15

Y1 - 2013/8/15

N2 - Background. In May 2011, the Food and Drug Administration approved fidaxomicin for the treatment of Clostridium difficile infection (CDI). It has been found to be noninferior to vancomycin; however, its cost-effectiveness for the treatment of CDI remains undetermined. Methods. We developed a decision analytic simulation model to determine the economic value of fidaxomicin for CDI treatment from the third-party payer perspective. We looked at CDI treatment in these 3 cases: (1) no fidaxomicin, (2) only fidaxomicin, and (3) fidaxomicin based on strain typing results. Results. The incremental cost-effectiveness ratio for fidaxomicin based on screening given current conditions was >$43.7 million per quality-adjusted life-year and using only fidaxomicin was dominated (ie, more costly and less effective) by the other 2 treatment strategies explored. The fidaxomicin strategy tended to remain dominated, even at lower costs. With approximately 50% of CDI due to the NAP1/BI/027 strain, a course of fidaxomicin would need to cost ≤$150 to be cost-effective in the treatment of all CDI cases and between $160 and $400 to be cost-effective for those with a non-NAP1/BI/027 strain (ie, treatment based on strain typing). Conclusions. Given the current cost and NAP1/BI/027 accounting for approximately 50% of isolates, using fidaxomicin as a first-line treatment for CDI is not cost-effective. However, typing and treatment with fidaxomicin based on strain may be more promising depending on the costs of fidaxomicin.

AB - Background. In May 2011, the Food and Drug Administration approved fidaxomicin for the treatment of Clostridium difficile infection (CDI). It has been found to be noninferior to vancomycin; however, its cost-effectiveness for the treatment of CDI remains undetermined. Methods. We developed a decision analytic simulation model to determine the economic value of fidaxomicin for CDI treatment from the third-party payer perspective. We looked at CDI treatment in these 3 cases: (1) no fidaxomicin, (2) only fidaxomicin, and (3) fidaxomicin based on strain typing results. Results. The incremental cost-effectiveness ratio for fidaxomicin based on screening given current conditions was >$43.7 million per quality-adjusted life-year and using only fidaxomicin was dominated (ie, more costly and less effective) by the other 2 treatment strategies explored. The fidaxomicin strategy tended to remain dominated, even at lower costs. With approximately 50% of CDI due to the NAP1/BI/027 strain, a course of fidaxomicin would need to cost ≤$150 to be cost-effective in the treatment of all CDI cases and between $160 and $400 to be cost-effective for those with a non-NAP1/BI/027 strain (ie, treatment based on strain typing). Conclusions. Given the current cost and NAP1/BI/027 accounting for approximately 50% of isolates, using fidaxomicin as a first-line treatment for CDI is not cost-effective. However, typing and treatment with fidaxomicin based on strain may be more promising depending on the costs of fidaxomicin.

KW - Clostridium difficile

KW - Cost

KW - Economics

KW - fidaxomicin

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84880944583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880944583&partnerID=8YFLogxK

U2 - 10.1093/cid/cit346

DO - 10.1093/cid/cit346

M3 - Article

C2 - 23704121

AN - SCOPUS:84880944583

VL - 57

SP - 555

EP - 561

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 4

ER -